TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib

COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune prof...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Dandan, Yang, Xuexian O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. 2020
Materias:
Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156211/
https://www.ncbi.nlm.nih.gov/pubmed/32205092
http://dx.doi.org/10.1016/j.jmii.2020.03.005
_version_ 1783522167827202048
author Wu, Dandan
Yang, Xuexian O.
author_facet Wu, Dandan
Yang, Xuexian O.
author_sort Wu, Dandan
collection PubMed
description COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.
format Online
Article
Text
id pubmed-7156211
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.
record_format MEDLINE/PubMed
spelling pubmed-71562112020-04-15 TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib Wu, Dandan Yang, Xuexian O. J Microbiol Immunol Infect Perspectives COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles. Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. 2020-06 2020-03-11 /pmc/articles/PMC7156211/ /pubmed/32205092 http://dx.doi.org/10.1016/j.jmii.2020.03.005 Text en © 2020 Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Perspectives
Wu, Dandan
Yang, Xuexian O.
TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib
title TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib
title_full TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib
title_fullStr TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib
title_full_unstemmed TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib
title_short TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib
title_sort th17 responses in cytokine storm of covid-19: an emerging target of jak2 inhibitor fedratinib
topic Perspectives
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156211/
https://www.ncbi.nlm.nih.gov/pubmed/32205092
http://dx.doi.org/10.1016/j.jmii.2020.03.005
work_keys_str_mv AT wudandan th17responsesincytokinestormofcovid19anemergingtargetofjak2inhibitorfedratinib
AT yangxuexiano th17responsesincytokinestormofcovid19anemergingtargetofjak2inhibitorfedratinib

Ejemplares similares